This pharmaceutical company has seen four positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved considerably higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s price action can turn into more strength down the road.
Lannett Company currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.
Other top-ranked Med-Drug stocks include Endocyte, Inc. (ECYT), Ariad Pharmaceuticals Inc. (ARIA) and BioCryst Pharmaceuticals, Inc. (BCRX). While ARIA and BCRX carry a Zacks Rank #2 (Buy), ECYT sports the same Zacks Rank as Lannett.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment